Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics reported a half-year loss after tax of $3.99 million for the period ended 31 December 2025, a 62.8% increase on the prior corresponding period, as revenues from ordinary activities fell to $3,712. The result reflects higher operating expenses of $5.15 million, driven mainly by increased clinical trial and development activity for lead asset PTX-100 and higher share-based payment costs.
Despite the deeper loss, Prescient’s net assets rose to $16.97 million from $11.39 million at 30 June 2025, supported by a combined $9.85 million capital raise through a placement and share purchase plan. The company also booked an estimated $1.15 million R&D tax rebate on eligible expenditure and saw its net tangible assets per share improve to 1.46 cents, reinforcing its funding position for ongoing development work.
The most recent analyst rating on (AU:PTX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Prescient Therapeutics Limited stock, see the AU:PTX Stock Forecast page.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a biotechnology company focused on developing targeted cancer therapies. Its pipeline includes clinical candidates such as PTX-100, and the company leverages Australia’s R&D Tax Incentive to support ongoing clinical trial and development activities in oncology.
Average Trading Volume: 2,213,435
Technical Sentiment Signal: Hold
Current Market Cap: A$67.3M
See more insights into PTX stock on TipRanks’ Stock Analysis page.